m i c r o N e b

Shopping cart

Subtotal: $4398.00

View cart Checkout

About Us

About
shape

25

Years Leadership

shape
About Us

Pioneering Inhaled Health Through Advanced Nebulization Technology

Founded in 2022 and headquartered in Saint Petersburg, Florida, microNeb combines clinical expertise with entrepreneurial drive to revolutionize healthcare delivery. Our patented inhalation devices utilize advanced piezo energy nebulization to establish 'Inhaled Health' as the new standard for precision medicine, emergency rescue, and wellness applications. With seven awarded patents and regulatory momentum building, we're transforming how medications are delivered, tracked, and optimized for individual health outcomes.

Icon

Regulatory Pathway Active

Designated Medical Device

Icon

7 Awarded Patents

25+ Years Healthcare Experience

DISCOVER MORE
Call Us On: (855) 204-7847
shape
TEAM MEMBER

See Our Skilled Expert Team

Brian Artze

Brian Artze

Co-Founder & CEO
Jesse Klein

Jesse Klein, DO

Co-Founder
Pradeep Albert

Pradeep Albert, MD

Co-Founder
Fadi Saba

Fadi Saba, MD

Co-Founder
Christine Nichols

Christine Nichols, RN

Co-Founder
David Condron

David Condron

Co-Founder
Icon

7+

Awarded Patents

Icon

25+

Years Leadership

Icon

5+

Product Verticals

Icon

$5M

Current Raise

Why
shape
WHY CHOOSE US

Defining the Future of Inhaled Health Technology

Pioneering breakthrough inhalation solutions that transform emergency rescue, clinical therapeutics, and lifestyle wellness. Our category-defining platform bridges clinical efficacy with consumer engagement, enabling predictive health analytics and personalized treatment protocols.

  • Regulatory Pathway Active
  • International PCT Protection
  • Generative Medicine™ Compliance Tracking
  • Global OEM Partnership
  • Federal Grant Funding
  • Life-Saving Emergency Systems
shape
INVESTMENT OPPORTUNITY

Join Our Mission to Transform Global Healthcare Delivery

Investment Opportunity

$5M

SAFE Agreement Target

$65M

Valuation Cap

25%

Discount

SAFE Agreement Structure

Use of Funds

  • FDA clinical and regulatory submissions (510(k), 505(b)(2), ANDA)
  • Tooling, production and launch inventory
  • Licensing, brand development and partner onboarding
  • Expansion of Generative Medicine™ + Bluetooth infrastructure and compliance dashboards

Market Opportunity

Growing inhalation drug delivery market

Protected IP

7 awarded patents with PCT protection

Revenue Streams

Medical, military, and wellness markets

Strategic Partnerships

Active talks with many major manufacturers

Exit Strategy

Our leadership team has extensive experience in building and exiting healthcare technology companies. Potential exit opportunities include:

  • Strategic acquisition by major medical device companies
  • Pharmaceutical company acquisition for drug delivery platform
  • Private equity rollup in digital health sector
  • IPO opportunity with platform expansion

Exit Potential: Strategic buyers typically pay premiums for FDA-cleared, patent-protected platforms with recurring revenue models.

Key Milestones 2026

Q1 2026

Regulatory Process
Clinical Trials

Q2 2026

FDA Clearance Process
Manufacturing

Q3 2026

FDA Clearance
Product Launch

Q4 2026

Market Expansion
Next Funding Round

Ready to Join the Revolution in Inhaled Health?

We're seeking strategic investors who share our vision of transforming global healthcare delivery. Join us in building the future of precision medicine.

REQUEST INVESTOR DECK

Accredited investors only. Securities offered under Regulation D, Rule 506(c).